Hematologic Malignancy
Aggressive B-Cell Non-Hodgkin Lymphoma
CI-CAN-00001751Explore in graph →
Hematologic115 active trials4 evidence items
- NCIt
- C178541
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001751Explore in graph →
Clinical trials
400 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (72)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02446457 | Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04425421 | Recommendations for the Treatment of Children With Burkitt's Lymphoma(GFALMB2019) | recruiting | — | 1,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 |
| clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04512716 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT04690595 | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | active not recruiting | Phase 1 | 24 | PeproMene Bio, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04883437 | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | recruiting | Phase 2 | 49 | Emory UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 396 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05583149 | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | active not recruiting | Phase 2 | 28 | Patrick C. Johnson, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | suspended | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05464329 | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04191187 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02568553 | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2025 | clinicaltrials |
| NCT01286272 | Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | completed | Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02337985 | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02996773 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | completed | Phase 1 | 50 | University of ArizonaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03375619 | Long-term Follow-up Study of Patients Receiving CAR-T Cells | recruiting | — | 500 | Medical College of WisconsinOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies(UPCC 25406) | terminated | Phase 1 / Phase 2 | 4 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | recruiting | Phase 2 | 227 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies(LONCA) | active not recruiting | Phase 1 | 11 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Early Phase 1 | 3 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06278181 | Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon | completed | — | 406 | Karolinska InstitutetOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT02393157 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL(O-ICE) | recruiting | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 348 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06940960 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02871219 | Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | terminated | Early Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06890065 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05377307 | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | recruiting | — | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | terminated | — | 25 | AIDS Malignancy ConsortiumNETWORK | 1 | May 11, 2025 | clinicaltrials |
| NCT06961500 | Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A(PROOF) | not yet recruiting | Phase 2 | 133 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01184885 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | completed | Early Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06060782 | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine(TCCA) | recruiting | Phase 1 | 28 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | active not recruiting | Phase 2 | 46 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06796517 | Immunotherapy in Lymphoma | recruiting | — | 72 | Sung-Soo ParkOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05263583 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | active not recruiting | Phase 2 | 14 | Cothera Bioscience, IncINDUSTRY | 2 | Jan 14, 2025 | clinicaltrials |
| NCT02112526 | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Acerta Pharma BVINDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2026source: clinicaltrials